TGFB2 and metabolic dysfunction-associated steatotic liver disease: A study by Di Mauro confirmed that serum RP11-128N14.5 and TGFB2/TGFB2-OT1 were upregulated in patients with NAS ≥ 5 compared with those with NAS ≤ 4, and the liver RP11-128N14.5 and TGFB2/TGFB2-OT1 were upregulated in severe NAFLD patients (NAS score ≥ 5, F = 3) compared with mild NAFLD patients (NAS ≤ 4, F = 0) and controls [43].